Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 5/2011

01-10-2011

The Radiologically Isolated Syndrome: Look (Again) Before You Treat

Authors: Rebecca Spain, Dennis Bourdette

Published in: Current Neurology and Neuroscience Reports | Issue 5/2011

Login to get access

Abstract

The advent and wide use of magnetic resonance brain imaging has led to in the unexpected detection of lesions that appear typical of multiple sclerosis (MS) in otherwise asymptomatic patients. Several cohorts of patients with the “radiologically isolated syndrome (RIS)” have been studied mainly retrospectively, and a proportion of them do go on to have clinical symptoms of MS. This has led to the not infrequent clinical conundrum of whether or not to treat patients with MRI lesions suggestive of MS, given the knowledge that MS disease-modifying therapies work best when given early in the disease course. However, the decision to proactively treat patients with RIS is countered by the increasing risks associated with MS disease-modifying therapies as well as the uncertain prognostic outcome of RIS. This review will highlight what is and is not known about the long-term outcomes of RIS and present recommendations for clinicians when faced with this challenging situation.
Literature
1.
PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group: PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56(12):1628–36.
2.
Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord. 2011;4(1):3–14.PubMedCrossRef
3.
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227–31.PubMedCrossRef
4.
Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1988;38(2):180–5.PubMed
5.
Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576–82.PubMedCrossRef
6.
Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898–904.PubMedCrossRef
7.
Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242–9.PubMedCrossRef
8.
Lyoo IK, Seol HY, Byun HS, Renshaw PF. Unsuspected multiple sclerosis in patients with psychiatric disorders: a magnetic resonance imaging study. J Neuropsychiatry Clin Neurosci. 1996;8(1):54–9.PubMed
9.
•• Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72(9):800–5. This study named and proposed diagnostic criteria for the RIS, and described the outcomes of a small cohort of patients with this condition. PubMedCrossRef
10.
Sellner J, Schirmer L, Hemmer B, Muhlau M. The radiologically isolated syndrome: take action when the unexpected is uncovered? J Neurol. 2010;257(10):1602–11.PubMedCrossRef
11.
Mackay RP, Hirano A. Forms of benign multiple sclerosis. Report of two “clinically silent” cases discovered at autopsy. Arch Neurol. 1967;17(6):588–600.PubMed
12.
13.
Castaigne P, Lhermitte F, Escourolle R, Castaigne P, Lhermitte F, Escourolle R, et al. Asymptomatic multiple sclerosis—3 cases (author’s transl). Rev Neurol (Paris). 1981;137(12):729–39.
14.
Gilbert JJ, Sadler M. Unsuspected multiple sclerosis. Arch Neurol. 1983;40(9):533–6.PubMed
15.
Engell T. A clinical patho-anatomical study of clinically silent multiple sclerosis. Acta Neurol Scand. 1989;79(5):428–30.PubMedCrossRef
16.
Heinsen H, Lockemann U, Puschel K. Unsuspected (clinically silent) multiple sclerosis. Quantitative investigations in one autoptic case. Int J Legal Med. 1995;107(5):263–6.PubMedCrossRef
17.
Barkhof F, Scheltens P, Kamphorst W. Pre-and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer’s disease. J Neurol Sci. 1993;117(1–2):175–8.PubMedCrossRef
18.
Lycklama à Nijeholt G, Barkhof F. Differences between subgroups of MS: MRI findings and correlation with histopathology. J Neurol Sci. 2003;206(2):173–4.PubMedCrossRef
19.
Seewann A, Kooi EJ, Roosendaal SD, et al. Translating pathology in multiple sclerosis: the combination of postmortem imaging, histopathology and clinical findings. Acta Neurol Scand. 2009;119(6):349–55.PubMedCrossRef
20.
Herndon RM, Rudick RA. Multiple sclerosis: the spectrum of severity. Arch Neurol. 1983;40(9):531–2.PubMed
21.
Wasay M, Rizvi F, Azeemuddin M, et al. Incidental MRI lesions suggestive of multiple sclerosis in asymptomatic patients in Karachi, Pakistan. J Neurol Neurosurg Psychiatry. 2011;82(1):83–5.PubMedCrossRef
22.
Traboulsee AL, Li DK. The role of MRI in the diagnosis of multiple sclerosis. Adv Neurol. 2006;98:125–46.PubMed
23.
de Seze J, Vermersch P. Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase. Mult Scler. 2005;11(4):395–7.PubMedCrossRef
24.
McDonnell GV, Cabrera-Gomez J, Calne DB, et al. Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: the subclinical stage of primary progressive multiple sclerosis may last 10 years. Mult Scler. 2003;9(2):204–9.PubMedCrossRef
25.
Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(Pt 11):2059–69.PubMedCrossRef
26.
Lebrun C, Bensa C, Debouverie M, et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry. 2008;79(2):195–8.PubMedCrossRef
27.
Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 2000;21(4):702–6.PubMed
28.
•• Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 2011;76(8):686–92. This study indicates that it may be possible to risk stratify patients with RIS based on lesion location. Further risk stratification will be important when deciding on therapeutic intervention for RIS. PubMedCrossRef
29.
Bourdette D, Yadav V. The radiologically isolated syndrome revisited: when is it presymptomatic multiple sclerosis? Neurology. 2011;76(8):680–1.PubMedCrossRef
30.
Siva A, Saip S, Altintas A, et al. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease. Mult Scler. 2009;15(8):918–27.PubMedCrossRef
31.
Sierra-Marcos A, Mitjana R, Castillo J, et al. Demyelinating lesions as incidental findings in magnetic resonance imaging: a study of 11 cases with clinico-radiological follow-up and a review of the literature. Rev Neurol. 2010;51(3):129–34.PubMed
32.
Schumacker GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552–68.PubMedCrossRef
33.
CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology. 2002;59(7):998–1005.
34.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121–7.PubMedCrossRef
35.
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840–6.PubMedCrossRef
36.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.PubMedCrossRef
37.
Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007;6(8):677–86.PubMedCrossRef
38.
Swanton JK, Fernando K, Dalton CM, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2006;77(7):830–3.PubMedCrossRef
39.
Rolak LA, Fleming JO. The differential diagnosis of multiple sclerosis. Neurologist. 2007;13(2):57–72.PubMedCrossRef
40.
Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124–40.PubMedCrossRef
41.
Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463–72.PubMedCrossRef
42.
• Chard DT, Dalton CM, Swanton J, et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2011;82(2):176–9. This looks at the long-term outcomes of CIS, which are important when conducting risk/benefit considerations of MS therapies in early stages of disease. PubMedCrossRef
43.
Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. Lancet Neurol. 2006;5(10):841–52.PubMedCrossRef
44.
Korteweg T, Uitdehaag BM, Knol DL, et al. Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. Eur Radiol. 2007;17(1):67–71.PubMedCrossRef
45.
Seewann A, Enzinger C, Filippi M, et al. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: a review of reported findings. J Neurol. 2008;255(1):1–10.PubMedCrossRef
46.
Lebrun C, Blanc F, Brassat D, et al. CFSEP: cognitive function in radiologically isolated syndrome. Mult Scler. 2010;16(8):919–25.PubMedCrossRef
Metadata
Title
The Radiologically Isolated Syndrome: Look (Again) Before You Treat
Authors
Rebecca Spain
Dennis Bourdette
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Neurology and Neuroscience Reports / Issue 5/2011
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-011-0213-z

Other articles of this Issue 5/2011

Current Neurology and Neuroscience Reports 5/2011 Go to the issue

Clinical Trial Report

Cognitive Impairment and MS: Searching for Effective Therapies

ReviewPaper

Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions

ReviewPaper

Cognitive Impairment in Huntington Disease: Diagnosis and Treatment

ReviewPaper

Advances in Epigenetics and Epigenomics for Neurodegenerative Diseases

ReviewPaper

Role of Cerebrospinal Fluid and Plasma Biomarkers in the Diagnosis of Neurodegenerative Disorders and Mild Cognitive Impairment

ReviewPaper

Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine